MK 7145

Drug Profile

MK 7145

Alternative Names: MK-7145

Latest Information Update: 26 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antihypertensives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 15 Feb 2015 Discontinued - Phase-I for Hypertension in Australia and New Zealand (PO)
  • 15 Feb 2015 Merck terminates a phase I trial in Hypertension in Australia and New Zealand (PO) (NCT01558674)
  • 31 Oct 2014 Discontinued - Phase-I for Hypertension in South Africa (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top